乳腺癌组织中E-选择素及其配体的表达及临床意义

目的:探讨乳腺癌组织中E-选择素(E-selectin)及其配体sLe-X(SialylLewis-X)的表达状况及其与肿瘤分化、转移及预后的关系。方法:采用免疫组化技术检测56例乳腺癌及癌旁组织中E-Selectin和sLe-X的表达,分析其表达水平与淋巴转移及临床病理特征之间的关系。20例乳腺纤维瘤标本为对照。结果:E-选择素和sLe-X在乳腺癌组织、癌旁组织、乳腺纤维瘤中阳性表达率分别为82.14%(46/56)、67.86%(38/56)、15.00%(3/20);73.21%(41/56)、58.93%(33/56)、30.00%(6/20)。E-选择素及sLe-X在乳腺癌组织中的表达显著高于癌旁组织及乳腺纤维癌中的表达(P<0.01);有淋巴结转移的乳腺癌组织sLe-X的表达高于无转移组(P<0.01),而E-Selectin在两组间的表达差异无统计学意义(P>0.05)。乳癌组织中E-选择素的表达与ER特征(P=0.001)、肿瘤分期(P=0.026)、肿瘤分化程度(P=0.013)、肿瘤直径(P=0.01)明显相关。单因素分析显示E-选择素表达状态与生存率相关(P=0.027)。结论:E-选择素和SLe-X协同介导了乳腺癌的发生发展及淋巴结转移。E-选择素可能是预测乳腺癌转移和预后的分子标志。

Expression and clinical significance of E-selectin and its ligand-sLe-X in breast carcinoma

Objective:To investigate the level of E-selectin and its ligand-sLe-X expression in breast carcinoma and its relation with differentiation,metastasis and prognosis.Methods:Immunohistochemistry was used to detect the rate of E-selectin and sLe-X in tumor tissues and adjacent normal tissues in 56 samples of breast cancer.A control group coinsisted of 20 patients with a benign breast tumor.Results:The positive rate of E-selectin and ligand-sLe-X in breast cancer tissues,adjacent normal tissues and benign tissues were 82.14%(46/56)vs 73.21%(41/56),67.86%(38/56)vs 58.93%(33/56),and 15.00%(3/20)vs 30.00%(6/20),respectively.The expression of the E-Selectin and SLe-X breast cancer tissues was significantly higher than in adjacent normal and benign tissues'(P<0.01) and so was the expression of SLe-X(P<0.01) but not E-Selectin in the metastasis group(P>0.05).The expression of E-selectin in breast cancer was significantly higher in women with oestrogen receptor-negative tumors(P=0.001),poorly differentiated tumor(P=0.013),more advanced tumor node metastasis(TNM) stage(P=0.026) and the diameter of tumors(P=0.01).Univariate analysis showed that there may be an association between overexpression of E-selectin and a worse prognosis(P=0.027).Conclusions:E-Selectin and SLe-X play an collaborate role in the lymph metastasis and carcinogenesis of breast cancer.E-selectin as a potent marker may contribute to diagnosis of metastasis and prognosis for breast cancer patients.It may play an important role in targeting and individualized treatment of breast cancer.